Jason L. Eriksen - Publications

Affiliations: 
University of Houston, Houston, TX, United States 
Area:
Alzheimer's disease

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Womack TR, Vollert CT, Ohia-Nwoko O, Schmitt M, Montazari S, Beckett TL, Mayerich D, Murphy MP, Eriksen JL. Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's Disease. Frontiers in Cellular Neuroscience. 16: 769347. PMID 35197825 DOI: 10.3389/fncel.2022.769347  0.763
2020 Hong J, Hong SG, Lee J, Park JY, Eriksen JL, Rooney BV, Park Y. Exercise training ameliorates cerebrovascular dysfunction in a murine model of Alzheimer's Disease: Role of the P2Y2 receptor and endoplasmic reticulum stress. American Journal of Physiology. Heart and Circulatory Physiology. PMID 32383993 DOI: 10.1152/Ajpheart.00129.2020  0.353
2020 Guo J, Artur C, Womack T, Eriksen JL, Mayerich D. Multiplex protein-specific microscopy with ultraviolet surface excitation. Biomedical Optics Express. 11: 99-108. PMID 32010503 DOI: 10.1364/Boe.11.000099  0.717
2020 Womack T, Eriksen JL. Effects of Prostacyclin Signaling on Alzheimer’s Disease Associated Pathologies The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05459  0.723
2018 Govyadinov PA, Womack T, Chen G, Mayerich D, Eriksen J. Robust Tracing and Visualization of Heterogeneous Microvascular Networks. Ieee Transactions On Visualization and Computer Graphics. PMID 29993636 DOI: 10.1109/Tvcg.2018.2818701  0.705
2018 Jarvela TS, Womack T, Georgiou P, Gould TD, Eriksen JL, Lindberg I. 7B2 chaperone knockout in APP model mice results in reduced plaque burden. Scientific Reports. 8: 9813. PMID 29955078 DOI: 10.1038/S41598-018-28031-7  0.754
2018 Artur CG, Womack T, Zhao F, Eriksen JL, Mayerich D, Shih WC. Plasmonic nanoparticle-based expansion microscopy with surface-enhanced Raman and dark-field spectroscopic imaging. Biomedical Optics Express. 9: 603-615. PMID 29552397 DOI: 10.1364/Boe.9.000603  0.713
2016 Tanifum EA, Ghaghada K, Vollert C, Head E, Eriksen JL, Annapragada A. A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. Journal of Alzheimer's Disease : Jad. PMID 27031484 DOI: 10.3233/Jad-151124  0.43
2014 Ohia-Nwoko O, Montazari S, Lau YS, Eriksen JL. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Molecular Neurodegeneration. 9: 54. PMID 25432085 DOI: 10.1186/1750-1326-9-54  0.355
2014 Dao AT, Zagaar MA, Salim S, Eriksen JL, Alkadhi KA. Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer's disease. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 593-602. PMID 24229510 DOI: 10.1017/S1461145713001351  0.304
2014 Hoshino A, Helwig M, Rezaei S, Berridge C, Eriksen JL, Lindberg I. A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease. Journal of Neurochemistry. 128: 419-30. PMID 24102330 DOI: 10.1111/Jnc.12454  0.466
2013 Vollert C, Forkuo GS, Bond RA, Eriksen JL. Chronic treatment with DCPCX, an adenosine A(1) antagonist, worsens long-term memory. Neuroscience Letters. 548: 296-300. PMID 23748072 DOI: 10.1016/J.Neulet.2013.05.052  0.304
2013 Hazra A, Gu F, Aulakh A, Berridge C, Eriksen JL, Ziburkus J. Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. Plos One. 8: e64318. PMID 23691195 DOI: 10.1371/Journal.Pone.0064318  0.389
2013 Dao AT, Zagaar MA, Levine AT, Salim S, Eriksen JL, Alkadhi KA. Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. Current Alzheimer Research. 10: 507-15. PMID 23627709 DOI: 10.2174/1567205011310050006  0.337
2013 Helwig M, Hoshino A, Berridge C, Lee SN, Lorenzen N, Otzen DE, Eriksen JL, Lindberg I. The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. The Journal of Biological Chemistry. 288: 1114-24. PMID 23172224 DOI: 10.1074/Jbc.M112.417071  0.423
2012 Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, Pourgarzham H, Kamath R, Espinosa G, Cook SC, Eriksen JL, Annapragada A. Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice. Plos One. 7: e48515. PMID 23119043 DOI: 10.1371/Journal.Pone.0048515  0.452
2012 Alkadhi K, Eriksen J. The complex and multifactorial nature of Alzheimer's disease. Current Neuropharmacology. 9: 586. PMID 22654718 DOI: 10.2174/157015911798376235  0.394
2011 Sun L, Eriksen JL. Recent insights into the involvement of progranulin in frontotemporal dementia. Current Neuropharmacology. 9: 632-42. PMID 22654721 DOI: 10.2174/157015911798376361  0.401
2010 Eriksen JL. The enigmatic roles of microglial versus neuronal progranulin in neurological disease. Acta Neuropathologica. 119: 107-9. PMID 20012633 DOI: 10.1007/S00401-009-0623-Z  0.302
2009 Cook C, Gass J, Dunmore J, Tong J, Taylor J, Eriksen J, McGowan E, Lewis J, Johnston J, Petrucelli L. Aging is not associated with proteasome impairment in UPS reporter mice. Plos One. 4: e5888. PMID 19517018 DOI: 10.1371/Journal.Pone.0005888  0.341
2008 Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics. 17: 3631-42. PMID 18723524 DOI: 10.1093/Hmg/Ddn257  0.461
2008 Eriksen JL, Zehr C, Lewis J. Biologic models of neurodegenerative disorders. Handbook of Clinical Neurology. 89: 173-88. PMID 18631742 DOI: 10.1016/S0072-9752(07)01216-X  0.33
2008 Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, et al. Substrate-targeting gamma-secretase modulators. Nature. 453: 925-9. PMID 18548070 DOI: 10.1038/Nature07055  0.732
2008 Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration. Journal of Neurochemistry. 104: 287-97. PMID 17953663 DOI: 10.1111/J.1471-4159.2007.04968.X  0.316
2007 Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends in Pharmacological Sciences. 28: 536-43. PMID 17900710 DOI: 10.1016/J.Tips.2007.09.004  0.405
2007 Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. Bmc Neuroscience. 8: 54. PMID 17650315 DOI: 10.1186/1471-2202-8-54  0.738
2007 Eriksen JL, Janus CG. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behavior Genetics. 37: 79-100. PMID 17072762 DOI: 10.1007/S10519-006-9118-Z  0.398
2006 Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, ... ... Eriksen J, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 442: 916-9. PMID 16862116 DOI: 10.1038/Nature05016  0.507
2006 Le Corre S, Klafki HW, Plesnila N, Hübinger G, Obermeier A, Sahagún H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 103: 9673-8. PMID 16769887 DOI: 10.1073/Pnas.0602913103  0.541
2006 McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends in Genetics : Tig. 22: 281-9. PMID 16567017 DOI: 10.1016/J.Tig.2006.03.007  0.562
2006 Lewis J, Zehr C, Andorfer C, Eriksen J, Knight J, Yue M, Robinson T, Berger Z, Hanna A, Dickson DW, Janus C, McGowan E, Hutton M. O4-05-01: Methods of cell death and recovery in the rTg4510 and iP301L inducible mouse models of tauopathy Alzheimer's & Dementia. 2: S84-S84. DOI: 10.1016/J.Jalz.2006.05.327  0.434
2006 Eriksen J, Zehr C, Berger Z, Robinson T, Lewis J, Hutton M. P3-293: Tau clearance through protein degradation pathways Alzheimer's & Dementia. 2: S461-S462. DOI: 10.1016/J.Jalz.2006.05.1562  0.483
2006 Hutton M, Melquist S, Baker M, Zehr C, McGowan E, Dickson D, Eriksen J, Ashe K, Stephan D, Lewis J. S2-02-06: The tauopathies: From genetics to animal models Alzheimer's & Dementia. 2: S26-S26. DOI: 10.1016/J.Jalz.2006.05.086  0.433
2005 McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 47: 191-9. PMID 16039562 DOI: 10.1016/J.Neuron.2005.06.030  0.739
2005 Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L. Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. Current Alzheimer Research. 2: 231-8. PMID 15974923 DOI: 10.2174/1567205053585927  0.546
2005 Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nature Medicine. 11: 545-50. PMID 15834426 DOI: 10.1038/Nm1235  0.738
2004 Hutton M, Melrose H, Zehr C, McGowan E, Dickson DW, Yen S, Kehoe K, Taylor J, Eriksen J, Petrucelli L, Lewis J. P4-422 Mechanism of neurofibrillary degeneration in a mouse model of tauopathy and progress towards identification of a therapeutic target Neurobiology of Aging. 25: S594. DOI: 10.1016/S0197-4580(04)81978-X  0.486
2004 Eriksen J, Kehoe K, Taylor J, Hutton M, Petrucelli L. P3-389 HSP70 prevents α-synuclein inhibition of the proteasome Neurobiology of Aging. 25: S466. DOI: 10.1016/S0197-4580(04)81537-9  0.435
2004 Pickford F, Onstead-Cardinale L, Eriksen J, Murphy P, Pritam D, Kim J, Dolios G, Wang R, Dickson DW, Golde T, McGowan E. P2-090 ABETA42 is required for amyloid deposition in transgenic mice Neurobiology of Aging. 25: S249. DOI: 10.1016/S0197-4580(04)80837-6  0.569
2004 Golde TE, Eriksen J, Nicolle M, Murphy MP, Kukar T, Monnier T, Prescott S, Wright S, Chevallier N, Sagi S, Das P, Koo EH. O3-06-02 Selective Abeta42 modifying agents: effects on Abeta deposition and behavior in TG2576 mice Neurobiology of Aging. 25: S64. DOI: 10.1016/S0197-4580(04)80215-X  0.721
2004 Eriksen JL, Petrucelli L. Parkinson's disease - Molecular mechanisms of disease Drug Discovery Today: Disease Mechanisms. 1: 399-405. DOI: 10.1016/J.Ddmec.2004.11.016  0.319
2003 Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. The Journal of Clinical Investigation. 112: 440-9. PMID 12897211 DOI: 10.1172/Jci18162  0.588
2003 Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. The Journal of Biological Chemistry. 278: 31831-7. PMID 12805356 DOI: 10.1074/Jbc.M303592200  0.518
2003 Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. The Journal of Biological Chemistry. 278: 31825-30. PMID 12805355 DOI: 10.1074/Jbc.M303588200  0.534
2003 Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. The Journal of Biological Chemistry. 278: 30748-54. PMID 12777371 DOI: 10.1074/Jbc.M304824200  0.562
2002 Golde TE, Eriksen JL, Weggen S, Sagi SA, Koo EH. Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease Drug Development Research. 56: 415-420. DOI: 10.1002/Ddr.10093  0.575
2001 Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414: 212-6. PMID 11700559 DOI: 10.1038/35102591  0.584
Show low-probability matches.